Research on mesenchymal stromal cell therapy is ongoing, with some studies indicating promise for treating conditions such as silicosis, knee osteoarthritis, and vascular damage. However, limitations and challenges in clinical translation, including standardization and heterogeneity, are also being reported. The therapy is being explored for various applications, including injectable treatments for corneal and joint-related issues.